1
|
Schneider S, Ferte T, Ducharme O, Dousset L, Prey S, Dutriaux C, Gerard E, Beylot-Barry M, Pham-Ledard A. Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas. J Cancer Res Clin Oncol 2024; 150:133. [PMID: 38492114 PMCID: PMC10944410 DOI: 10.1007/s00432-023-05593-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Accepted: 12/22/2023] [Indexed: 03/18/2024]
Abstract
PURPOSE Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in white-skinned populations. There is little information on the epidemiology of cSCC, and even less on advanced cases (acSCC). Therefore, we analyzed acSCC patients to describe their characteristics, management, and outcomes over time. METHODS A single-center retrospective study was conducted over a period of 5 years, including all patients who started systemic therapy for acSCC. The patient characteristics, cSCC management, response to therapy, and survival were recorded. Patients were stratified into equal chronological periods (periods 1 and 2). A subgroup analysis was performed to compare patients who received immunotherapy (group 1) with those who did not (group 2). RESULTS The study included 127 patients, and patient numbers increased by an average of 19.7% per year. Most patients were male (88/127), elderly (mean 81.6 years), with comorbidities, and 27.6% were immunocompromised. The median overall survival (OS) was higher in period 2 (20 months) than in period 1 (10 months) (hazard ratio [95% confidence interval] = 0.62 [0.39; 0.98], p = 0.04). The risk of progression increased with age and immunosuppression. Of the 64 patients who received second-line therapy, 38 had immunotherapy (group 1) and 26 received other therapies (group 2). Immunotherapy reduced mortality and progression by 71% (p = 0.004) and 67% (p = 0.002), respectively. CONCLUSIONS Patients with acSCC are usually very frail and elderly. OS increased over time, with a twofold improvement between periods 1 and 2, whereas progression-free survival (PFS) did not increase. Access to immunotherapy reduced mortality in a majority of patients in period 2. Immunosuppression and advanced age were associated with lower PFS.
Collapse
Affiliation(s)
- Sophie Schneider
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France
| | - Thomas Ferte
- Public Health Centre, Methodological Support Unit for Clinical and Epidemiological Research, CHU Bordeaux, 33000, Bordeaux, France
| | - Océane Ducharme
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France
| | - Léa Dousset
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France
- Public Health Centre, Methodological Support Unit for Clinical and Epidemiological Research, CHU Bordeaux, 33000, Bordeaux, France
- INSERM U1312, BRIC, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, University Bordeaux, 33076, Bordeaux, France
| | - Sorilla Prey
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France
- Public Health Centre, Methodological Support Unit for Clinical and Epidemiological Research, CHU Bordeaux, 33000, Bordeaux, France
- INSERM U1312, BRIC, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, University Bordeaux, 33076, Bordeaux, France
| | - Caroline Dutriaux
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France
- Public Health Centre, Methodological Support Unit for Clinical and Epidemiological Research, CHU Bordeaux, 33000, Bordeaux, France
- INSERM U1312, BRIC, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, University Bordeaux, 33076, Bordeaux, France
| | - Emilie Gerard
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France
| | - Marie Beylot-Barry
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France
- Public Health Centre, Methodological Support Unit for Clinical and Epidemiological Research, CHU Bordeaux, 33000, Bordeaux, France
- INSERM U1312, BRIC, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, University Bordeaux, 33076, Bordeaux, France
| | - Anne Pham-Ledard
- Dermatology Department, Hôpital Saint André, CHU Bordeaux, 1 Avenue Jean-Burguet, 33000, Bordeaux, France.
- Public Health Centre, Methodological Support Unit for Clinical and Epidemiological Research, CHU Bordeaux, 33000, Bordeaux, France.
- INSERM U1312, BRIC, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, University Bordeaux, 33076, Bordeaux, France.
| |
Collapse
|
2
|
Dupont A, Vergara R, Pacaud A, Dequidt L, Dutriaux C, Saunier V, Caumont C, Jullie ML, Taïeb A, Morice-Picard F, Dousset L. Giant syringocystadenocarcinoma papilliferum with conjunctival recurrence: Possible Schimmelpenning syndrome with postzygotic G13R HRAS and K601N BRAF signature. J Eur Acad Dermatol Venereol 2023; 37:e1420-e1422. [PMID: 37458522 DOI: 10.1111/jdv.19346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 07/12/2023] [Indexed: 07/21/2023]
Affiliation(s)
- Aurore Dupont
- Department of Dermatology and Pediatric Dermatology, Hospital of Bordeaux, Bordeaux, France
- National Reference Center for Rare Skin Disorders, Hospital of Bordeaux, Bordeaux, France
| | - Rémi Vergara
- Department of Pathology, Hospital of Bordeaux, Pessac, France
| | - Alizé Pacaud
- Department of Dermatology and Pediatric Dermatology, Hospital of Bordeaux, Bordeaux, France
- National Reference Center for Rare Skin Disorders, Hospital of Bordeaux, Bordeaux, France
| | - Laure Dequidt
- Department of Dermatology and Pediatric Dermatology, Hospital of Bordeaux, Bordeaux, France
- National Reference Center for Rare Skin Disorders, Hospital of Bordeaux, Bordeaux, France
| | - Caroline Dutriaux
- Department of Dermatology and Pediatric Dermatology, Hospital of Bordeaux, Bordeaux, France
- National Reference Center for Rare Skin Disorders, Hospital of Bordeaux, Bordeaux, France
| | | | - Charline Caumont
- Laboratory of Tumor Biology and Tumor Biobank, Hospital of Bordeaux, Pessac, France
- INSERM U1312, TRIO2, University of Bordeaux, Bordeaux, France
| | | | - Alain Taïeb
- Department of Dermatology and Pediatric Dermatology, Hospital of Bordeaux, Bordeaux, France
- National Reference Center for Rare Skin Disorders, Hospital of Bordeaux, Bordeaux, France
- INSERM U1312, TRIO2, University of Bordeaux, Bordeaux, France
| | - Fanny Morice-Picard
- Department of Dermatology and Pediatric Dermatology, Hospital of Bordeaux, Bordeaux, France
- National Reference Center for Rare Skin Disorders, Hospital of Bordeaux, Bordeaux, France
- INSERM U1312, TRIO2, University of Bordeaux, Bordeaux, France
| | - Léa Dousset
- Department of Dermatology and Pediatric Dermatology, Hospital of Bordeaux, Bordeaux, France
- National Reference Center for Rare Skin Disorders, Hospital of Bordeaux, Bordeaux, France
- INSERM U1312, TRIO2, University of Bordeaux, Bordeaux, France
| |
Collapse
|
3
|
Guicheney M, Ducharme O, Caumont C, Gerard E, Dousset L, Beylot-Barry M, Merlio JP, Gros A, Pham-Ledard A. Assessment of Liquid Biopsy in Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type. J Invest Dermatol 2023; 143:1326-1329.e5. [PMID: 36693617 DOI: 10.1016/j.jid.2022.12.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 12/21/2022] [Accepted: 12/26/2022] [Indexed: 01/22/2023]
Affiliation(s)
| | - Océane Ducharme
- Dermatology Department, CHU Bordeaux, Bordeaux, France; Bordeaux Institute of Oncology, BRIC U1312, INSERM, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, Univ. Bordeaux, Bordeaux, France
| | - Charline Caumont
- Bordeaux Institute of Oncology, BRIC U1312, INSERM, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, Univ. Bordeaux, Bordeaux, France; Department of Tumor Biology, CHU Bordeaux, Pessac, France
| | - Emilie Gerard
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - Léa Dousset
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - Marie Beylot-Barry
- Dermatology Department, CHU Bordeaux, Bordeaux, France; Bordeaux Institute of Oncology, BRIC U1312, INSERM, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, Univ. Bordeaux, Bordeaux, France
| | - Jean-Philippe Merlio
- Bordeaux Institute of Oncology, BRIC U1312, INSERM, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, Univ. Bordeaux, Bordeaux, France; Department of Tumor Biology, CHU Bordeaux, Pessac, France
| | - Audrey Gros
- Bordeaux Institute of Oncology, BRIC U1312, INSERM, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, Univ. Bordeaux, Bordeaux, France; Department of Tumor Biology, CHU Bordeaux, Pessac, France
| | - Anne Pham-Ledard
- Dermatology Department, CHU Bordeaux, Bordeaux, France; Bordeaux Institute of Oncology, BRIC U1312, INSERM, Team 5 Translational Research on Oncodermatology and Rare Skin Diseases, Univ. Bordeaux, Bordeaux, France.
| |
Collapse
|
4
|
Dousset L, Michon P, Mahfouf W, Muzotte E, Guzzo G, Beylot-Barry M, Rezvani H. 480 Inhibition of DHODH reduces efficiently tumor growth in a subgroup of cutaneous squamous cell carcinoma with a particular metabolic profile. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Dousset L, Poizeau F, Robert C, Mansard S, Mortier L, Caumont C, Routier É, Dupuy A, Rouanet J, Battistella M, Greliak A, Cappellen D, Galibert MD, Allayous C, Lespagnol A, Gerard É, Kerneuzet I, Roy S, Dutriaux C, Merlio JP, Vergier B, Schrock AB, Lee J, Ali SM, Kammerer-Jacquet SF, Lebbé C, Beylot-Barry M, Boussemart L. Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy. JCO Precis Oncol 2021; 5:PO.21.00084. [PMID: 34950838 PMCID: PMC8691497 DOI: 10.1200/po.21.00084] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 08/04/2021] [Accepted: 11/06/2021] [Indexed: 12/15/2022] Open
Abstract
Emerging evidence suggests a correlation between the tumor mutational burden (TMB) and the response to programmed cell death-1 protein (PD-1) monotherapy across multiple cancer types. In skin cancers, as high TMB is mostly because of ultraviolet (UV) exposure, we hypothesized a correlation between the primary melanoma cutaneous location according to sun exposure and response to anti–PD-1 monotherapy. The location of the primary melanoma in a sun-exposed area can help choosing first-line advanced melanoma treatment.![]()
Collapse
Affiliation(s)
- Léa Dousset
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Florence Poizeau
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research], Rennes, France
| | - Caroline Robert
- Institut de Cancérologie Gustave Roussy et Université Paris-Saclay, Villejuif, France
| | - Sandrine Mansard
- Department of Medical Oncology, Estaing Hospital, Clermont-Ferrand, France
| | - Laurent Mortier
- Department of Dermatology, CHU de Lille, Université de Lille, Lille, France
| | - Charline Caumont
- Department of Tumor Pathology and Tumor Bank, University Hospital of Bordeaux, France
- INSERM U1053, UMR Bariton, Bordeaux University, Bordeaux, France
| | - Émilie Routier
- Institut de Cancérologie Gustave Roussy et Université Paris-Saclay, Villejuif, France
| | - Alain Dupuy
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research], Rennes, France
| | - Jacques Rouanet
- Department of Medical Oncology, Estaing Hospital, Clermont-Ferrand, France
| | - Maxime Battistella
- Department of Pathology, AP-HP, Saint-Louis University Hospital, Paris, France
| | - Anna Greliak
- Department of Dermatology, CHU de Lille, Université de Lille, Lille, France
| | - David Cappellen
- Department of Tumor Pathology and Tumor Bank, University Hospital of Bordeaux, France
| | - Marie-Dominique Galibert
- Hospital University of Rennes, Department of Molecular Genetics and Genomic, Rennes, France
- Université Rennes, CNRS, IGDR, UMR 6290, Rennes, France
| | - Clara Allayous
- Université de Paris, AP-HP Dermatology Department, INSERM U976, Saint-Louis Hospital, France
| | - Alexandra Lespagnol
- Hospital University of Rennes, Department of Molecular Genetics and Genomic, Rennes, France
- Université Rennes, CNRS, IGDR, UMR 6290, Rennes, France
| | - Émilie Gerard
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Inès Kerneuzet
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
| | - Séverine Roy
- Institut de Cancérologie Gustave Roussy et Université Paris-Saclay, Villejuif, France
| | - Caroline Dutriaux
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Jean-Philippe Merlio
- Department of Tumor Pathology and Tumor Bank, University Hospital of Bordeaux, France
| | - Beatrice Vergier
- Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | | | | | - Siraj M. Ali
- Foundation Medicine, Inc, Cambridge, MA
- EQRX Inc, Cambridge, MA
| | - Solène-Florence Kammerer-Jacquet
- Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, Rennes, France
- Department of Pathology, CHU de Rennes, Rennes, France
| | - Céleste Lebbé
- Université de Paris, AP-HP Dermatology Department, INSERM U976, Saint-Louis Hospital, France
| | - Marie Beylot-Barry
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - Lise Boussemart
- Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France
- Université Rennes, CNRS, IGDR, UMR 6290, Rennes, France
| |
Collapse
|
6
|
Dousset L, Pacaud A, Barnetche T, Kostine M, Dutriaux C, Pham-Ledard A, Beylot-Barry M, Gérard E, Prey S, Andreu N, Boniface K, Seneschal J. Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study. JAAD Int 2021; 5:112-120. [PMID: 34712997 PMCID: PMC8529074 DOI: 10.1016/j.jdin.2021.09.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/10/2021] [Indexed: 12/18/2022] Open
Abstract
Background Clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 (PD-1) remain unknown. Objective To better characterize the occurrence of vitiligo in patients receiving anti–PD-1. Methods The present single-center ambispective cohort study included patients with melanoma treated with anti–PD-1. Progression-free survival, overall survival, and objective tumor response were compared between patients with and those without vitiligo using Kaplan-Meier curves and the log-rank test. Demographic and clinical factors associated with vitiligo were evaluated using multivariate logistic regression. Results Of the 457 patients included in the study, vitiligo developed in 85 patients. The clinical presentation of vitiligo consisted of the presence of ovalar and multiple flecked white macules, mainly located on chronic sun-exposed areas. The presence of vitiligo was associated with a significant improvement in overall survival and progression-free survival (P < .001). A Cox proportional hazards model estimation demonstrated markedly improved survival in patients with vitiligo compared with those without vitiligo (aHR [overall survival], 0.20; 95% CI, 0.12-0.33; P < .001; and aHR [progression-free survival], 0.33; 95% CI, 0.23-0.47; P < .001). In the multivariate logistic regression analyses, men showed an independent increased risk of the development of vitiligo (odds ratio, 1.66). In contrast, the presence of pulmonary metastases was found to be an independent factor associated with a reduced risk of the development of vitiligo (odds ratio, 0.50). Limitations Single-center ambispective cohort. Conclusion Vitiligo in patients receiving anti–PD-1 for advanced melanoma is associated with a better outcome. A gender effect associated with the development of vitiligo will need further investigation.
Collapse
Affiliation(s)
- Léa Dousset
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France
| | - Alize Pacaud
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France
| | - Thomas Barnetche
- Department of Rheumatology, National Reference Center for Severe Systemic Autoimmune Diseases, FHU ACRONIM, Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France
| | - Marie Kostine
- Department of Rheumatology, National Reference Center for Severe Systemic Autoimmune Diseases, FHU ACRONIM, Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France
| | - Caroline Dutriaux
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.,U1035 INSERM, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux University, Bordeaux, France
| | - Anne Pham-Ledard
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France
| | - Marie Beylot-Barry
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France
| | - Emilie Gérard
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France
| | - Sorilla Prey
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.,U1035 INSERM, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux University, Bordeaux, France
| | - Nicolas Andreu
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France
| | - Katia Boniface
- U1035 INSERM, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux University, Bordeaux, France
| | - Julien Seneschal
- Department of Dermatology, National Centre for Rare Skin Disorders, University Hospital of Bordeaux, Bordeaux, France.,U1035 INSERM, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Bordeaux University, Bordeaux, France
| |
Collapse
|
7
|
Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 2021; 157:474-484. [PMID: 34649118 DOI: 10.1016/j.ejca.2021.08.036] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2019] [Revised: 07/30/2021] [Accepted: 08/04/2021] [Indexed: 02/07/2023]
Abstract
PURPOSE As gut microbiota composition is an important determinant of response to immune checkpoint inhibitors (ICIs), we examined the effect of various co-medications known for their interaction with microbiota, when given at ICI initiation. PATIENTS AND METHODS We identified patients with advanced cancer treated with ICI between May 2015 and September 2017 in our institution. Co-medications given within 1 month before or 1 month after the first administration of ICI were reviewed from medical records. Survival data were analysed with univariable Cox regression, and the combined effect of multiple factors was assessed with factor analysis of mixed data (FAMD). The impact of co-medications on immune-related adverse events (irAEs) occurrence was also assessed. RESULTS A total of 635 patients were included. Psychotropic drugs (41%), proton pump inhibitors (PPIs; 38%), angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II receptor blockers (ARBs; 32%), glucocorticoids (26%), antibiotics (24%), statins (21%) and morphine (20%) were the most prescribed co-medications. Baseline use of antibiotics, glucocorticoids >10 mg/day, PPIs, psychotropic drugs, morphine and insulin was associated with significantly shortened overall survival and decreased tumour response, whereas coadministration of statins, ACEs and/or ARBs, non-steroidal anti-inflammatory drugs, aspirin and oral antidiabetic drugs did not impact patient outcomes. Treatments that altered the response to ICI were also associated with a decreased incidence of irAEs. FAMD revealed the respective weight of each factor or co-medication on the oncological outcomes. CONCLUSION Co-medications must be carefully assessed at the time of ICI initiation and clinicians aware of their possible deleterious effect, notably for PPIs, glucocorticoids, antibiotics and psychotropic drugs.
Collapse
Affiliation(s)
- Marie Kostine
- Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France.
| | - Eleonora Mauric
- Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France
| | - Alice Tison
- Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France
| | - Thomas Barnetche
- Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France
| | | | | | - Léa Rouxel
- Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France
| | - Caroline Dutriaux
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - Léa Dousset
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - Sorilla Prey
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - Marie Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - Julien Seneschal
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - Rémi Veillon
- Department of Pulmonology, Bordeaux University Hospital, Bordeaux, France
| | | | - Amaury Daste
- Department of Oncology, Bordeaux University Hospital, Bordeaux, France
| | | | - Baptiste Sionneau
- Department of Oncology, Bordeaux University Hospital, Bordeaux, France
| | | | - Alain Ravaud
- Department of Oncology, Bordeaux University Hospital, Bordeaux, France
| | - Edouard Forcade
- Department of Hematology, Bordeaux University Hospital, Bordeaux, France
| | | | | |
Collapse
|
8
|
Michon P, Dousset L, Mahfouf W, Muzotte E, Moisan F, Rossignol R, Rezvani H. 256 Metabolic Vulnerabilities as Predictive Biomarkers and Therapeutic Targets in Skin Carcinogenesis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Michon P, Dousset L, Mahfouf W, Muzotte E, Faucheux C, Cario-André M, Rezvani H. LB799 Role of mitochondria in keratinocyte responses to acute UVB irradiation. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.07.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Bourlond F, Battistella M, Amici JM, Dousset L, Vergier B, Beylot-Barry M, Cribier B. Clinicopathologic analysis of trichoblastoma and comparison with nodular basal cell carcinoma. Ann Dermatol Venereol 2021; 148:177-182. [PMID: 34176642 DOI: 10.1016/j.annder.2021.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/15/2020] [Accepted: 03/18/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Trichoblastoma (TB) is an uncommon benign follicular tumour for which clinical data is limited since most reports originate from pathology studies. OBJECTIVE To describe the clinical aspects of TB. METHODS This is an ancillary study of a prospective multicentre cohort of 2710 clinically suspected basal cell carcinoma (BCC), including 935 nodular BCCs. Sixty-two cases were TB: they were analysed and compared to 935 nodular BCCs. RESULTS TB mostly occurred in females (61% vs. 43% for BCC, P<0.01) of mean age 63 years. They were located on the head and neck, mainly on the nose and forehead, in 87% of cases. The mean size was 8.1mm, 77% were<10mm (55% of BCCs, P<0.001), 8% were ulcerated (vs. 21% of BCCs, P<0.02), and 47% persisted for more than 1 year (34% of BCCs, P<0.05). Most cases had a clinical presentation similar to nodular BCC, except for 5 small, flat, white papules and 1 anfractuous plaque. LIMITATIONS Cases originated from a series of tumours clinically suspected as BCCs. DISCUSSION Some 2.6% of tumours clinically diagnosed as BCC are in fact TB. TB occurs on the head, are more frequent in women, and are smaller and of longer duration than BCC. In most cases, clinical diagnosis on clinical grounds is difficult.
Collapse
Affiliation(s)
- F Bourlond
- Dermatology Clinic, Strasbourg University Hospitals, 1, place de l'Hôpital, 67091 Strasbourg, France.
| | - M Battistella
- Pathology Department, Saint-Louis Hospital AP-HP, Paris University, INSERM U976, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J-M Amici
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - L Dousset
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - B Vergier
- Anatomic Pathology Department, Bordeaux University Hospital, Haut-Lévêque Hospital, avenue du Haut-Lévêque, 33604 Pessac, France
| | - M Beylot-Barry
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France; Inserm U1053, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - B Cribier
- Dermatology Clinic, Strasbourg University Hospitals, 1, place de l'Hôpital, 67091 Strasbourg, France
| |
Collapse
|
11
|
Dousset L, Martins C, Jacquemin C, Amico S, Schatton T, Boniface K, Seneschal J. Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with a high frequency of melanoma-infiltrating CXCR3 + resident memory CD8 + T cells and multiple chemokine pathways. Br J Dermatol 2021; 185:663-666. [PMID: 33894001 DOI: 10.1111/bjd.20405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 04/16/2021] [Accepted: 04/22/2021] [Indexed: 11/28/2022]
Affiliation(s)
- L Dousset
- Department of Dermatology and Paediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France.,INSERM U1035, BMGIC, Immuno-Dermatology, University of Bordeaux, Bordeaux, France
| | - C Martins
- INSERM U1035, BMGIC, Immuno-Dermatology, University of Bordeaux, Bordeaux, France
| | - C Jacquemin
- INSERM U1035, BMGIC, Immuno-Dermatology, University of Bordeaux, Bordeaux, France
| | - S Amico
- Department of Dermatology and Paediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | - T Schatton
- Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| | - K Boniface
- INSERM U1035, BMGIC, Immuno-Dermatology, University of Bordeaux, Bordeaux, France
| | - J Seneschal
- Department of Dermatology and Paediatric Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France.,INSERM U1035, BMGIC, Immuno-Dermatology, University of Bordeaux, Bordeaux, France
| |
Collapse
|
12
|
costedoat I, Leroy-Colavolpe V, Dousset L, Beylot-Barry M, Doutre M. Cellulite de Wells à type d’œdème récidivant du visage : 3 cas. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Guelimi R, Salle R, Dousset L, Assier H, Fourati S, Bhujoo Z, Barbarot S, Boulard C, Cazanave C, Colin A, Kostrzewa E, Lesort C, Levy Roy A, Lombart F, Marco Bonnet J, Marty L, Monfort JB, Riffaud L, Samimi M, Tardieu M, Sbidian E, Wolkenstein P, Le Cleach L, Beylot-Barry M. Non-acral skin manifestations during the COVID-19 epidemic: COVIDSKIN study by the French Society of Dermatology. J Eur Acad Dermatol Venereol 2021; 35:e539-e541. [PMID: 33914975 PMCID: PMC8242387 DOI: 10.1111/jdv.17322] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 03/26/2021] [Accepted: 04/16/2021] [Indexed: 01/08/2023]
Affiliation(s)
- R Guelimi
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - R Salle
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - L Dousset
- Dermatology Department, University Hospital Bordeaux, Bordeaux, France
| | - H Assier
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - S Fourati
- Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
| | - Z Bhujoo
- Dermatology Department, Grand Hôpital de l'Est Francilien, Jossigny, France
| | - S Barbarot
- Dermatology Department, Nantes Université, University Hospital of Nantes, UMR 1280 PhAN, INRAE, Nantes, France
| | - C Boulard
- Department of Dermatology, Le Havre Hospital, Le Havre, France
| | - C Cazanave
- Infectious and Tropical Diseases Department, CHU Bordeaux, Bordeaux, France
| | - A Colin
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - E Kostrzewa
- Dermatology Department, Hôpital Robert Boulin, Libourne, France
| | - C Lesort
- Dermatology Department, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | | | - F Lombart
- Dermatology, Amiens University Hospital Centre, Amiens, France
| | | | - L Marty
- Private Practice, Latresne, France
| | - J B Monfort
- AP-HP, Dermatology and Allergology Department, Hôpital Tenon, Sorbonne Université, Sorbonne University, Paris, France
| | | | - M Samimi
- Dermatology Department, University Hospital of Tours, INRA-University of Tours, ISP1282, Tours, France
| | - M Tardieu
- Dermatology Department, University Hospital of Grenoble Alpes, Grenoble, France
| | - E Sbidian
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - P Wolkenstein
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - L Le Cleach
- Dermatology Department, Hôpital Henri Mondor, APHP, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - M Beylot-Barry
- Dermatology Department, University Hospital Bordeaux, Bordeaux, France.,French Society of Dermatology, Paris, France
| |
Collapse
|
14
|
Valentin J, Gérard E, Ferte T, Prey S, Dousset L, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. J Geriatr Oncol 2021; 12:1110-1113. [PMID: 33736973 DOI: 10.1016/j.jgo.2021.02.026] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 01/06/2021] [Accepted: 02/24/2021] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) mostly affects older and frail patients. Cemiplimab is an anti-PD1 antibody used in this indication since its approval by the FDA and the EMA in 2019 after encouraging results from phase II trials. We aimed to evaluate cemiplimab safety in patients from daily practice. METHODS Retrospective and monocentric study including all patients who received at least one infusion of cemiplimab between August 2018 and September 2019. Adverse effects (AEs), treatment interruption, and efficacy were recorded (data cut-off, November 1st 2020). RESULTS Twenty-two patients were included, median age was 83 [55-93], 73% were Eastern Cooperative Oncology Group (ECOG) 0 or 1, 36% were immune compromised. After a median time on treatment of six months [0.7-22], seventeen patients (77%) experienced 24 AEs, comprising 45% serious AEs (SAEs) grade ≥ 3 and one SAE grade 5 (myositis). Patients who presented SAEs were all >65 years old. Nine patients (41%) definitively discontinued treatment due to AEs. Seventeen patients were evaluable, after a median follow-up of eleven months [1-22], 32% had an objective response (2 complete and 5 partial responses), 47% had controlled disease and 35% experienced progression. CONCLUSIONS In our cohort, safety seemed to be worse than in phase II trial with more treatment discontinuations due to cemiplimab toxicity, probably reflecting the distinct demographic and medical characteristics of patients in daily care.
Collapse
Affiliation(s)
- Julie Valentin
- Dermatology Department, CHU Bordeaux, F-33000 Bordeaux, France
| | - Emilie Gérard
- Dermatology Department, CHU Bordeaux, F-33000 Bordeaux, France
| | - Thomas Ferte
- Pôle de Santé Publique, Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique, CHU de Bordeaux, Bordeaux, France
| | - Sorilla Prey
- Dermatology Department, CHU Bordeaux, F-33000 Bordeaux, France; Univ. Bordeaux, INSERM U1035, F-33076 Bordeaux, France
| | - Léa Dousset
- Dermatology Department, CHU Bordeaux, F-33000 Bordeaux, France; Univ. Bordeaux, INSERM U1035, F-33076 Bordeaux, France
| | - Caroline Dutriaux
- Dermatology Department, CHU Bordeaux, F-33000 Bordeaux, France; Univ. Bordeaux, INSERM U1035, F-33076 Bordeaux, France
| | - Marie Beylot-Barry
- Dermatology Department, CHU Bordeaux, F-33000 Bordeaux, France; Univ. Bordeaux, INSERM U1053, Team 3 Oncogenesis of Cutaneous Lymphoma, F-33076 Bordeaux, France
| | - Anne Pham-Ledard
- Dermatology Department, CHU Bordeaux, F-33000 Bordeaux, France; Univ. Bordeaux, INSERM U1053, Team 3 Oncogenesis of Cutaneous Lymphoma, F-33076 Bordeaux, France.
| |
Collapse
|
15
|
Marescassier H, Dousset L, Beylot-Barry M, Célérier P, Vaillant L, Bedane C, Leclère F, Wierzbicka-Hainaut E, Masson Regnault M. Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma. Dermatology 2021; 237:1023-1028. [PMID: 33472195 DOI: 10.1159/000512889] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Accepted: 11/08/2020] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Vismodegib has shown clinical efficacy in the management of locally advanced basal cell carcinomas (laBCC). However, non-response to vismodegib is observed in 2-13.5% of patients in clinical studies. The purpose of this study was to identify factors associated with non-response to vismodegib in patients with laBCC. METHODS We carried out a retrospective multicenter study, including patients with laBCC treated with vismodegib, from July 2011 to May 2019. Response to treatment was assessed according to the RECIST 1.1 criteria. Patients were categorized as responders with a complete response or a partial response or non-responders with a stable disease or a progressive disease according to what has been observed during follow-up. Patient demographics, tumor profile, and treatment modalities were compared in responders and non-responders. RESULTS Eighty-three patients with laBCC were included in the study. Twenty-five (30.1%) were non-responders to vismodegib. History of treatment with radiotherapy, presence of muscle involvement and intermittent treatment with vismodegib were significantly associated with a non-response (p < 0.001, p = 0.025, p < 0.001). Bone involvement (p = 0.2) and morpheaform IaBCC subtype (p = 0.056) were more frequent in non-responders without reaching statistical significance. CONCLUSION In this study, non-response of laBCC to vismodegib therapy was associated with muscle involvement. Previous radiotherapy and intermittent use of vismodegib have been identified as causes favoring non-response to vismodegib. Due to the low numbers of patients included in the study, it is difficult to draw firm conclusions. Further studies are needed to confirm these data.
Collapse
Affiliation(s)
| | - Léa Dousset
- Department of Dermatology, CHU Bordeaux, Bordeaux, France
| | | | | | | | | | - Franck Leclère
- Department of Plastic Surgery, CHU Poitiers, Poitiers, France
| | - Ewa Wierzbicka-Hainaut
- Department of Dermatology, CHU Poitiers, Poitiers, France.,Laboratoire Inflammation, Tissus Epithéliaux et Cytokines (LITEC), EA4331, Université de Poitiers, Poitiers, France
| | - Marie Masson Regnault
- Department of Dermatology, CHU Poitiers, Poitiers, France, .,Laboratoire Inflammation, Tissus Epithéliaux et Cytokines (LITEC), EA4331, Université de Poitiers, Poitiers, France,
| |
Collapse
|
16
|
Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, Bourseau Quetier C, Cambon L, Cazanave C, Colin A, Kostrzewa E, Lesort C, Levy Roy A, Lombart F, Marco-Bonnet J, Monfort J, Samimi M, Tardieu M, Wolkenstein P, Sbidian E, Beylot-Barry M. La majorité des engelures observées durant l’épidémie de COVID-19 ne semblent pas dues à l’infection par le SRAS-Cov-2. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Dupont A, Pacaud A, Saunier V, Caumont C, Jullie ML, Taïeb A, Morice-Picard F, Dousset L. Récidive conjonctivale d’un syringocystadénocarcinome papillifère sur syndrome de Schimmelpenning associé aux mutations post-zygotiques HRAS et BRAF. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Pacaud A, Dousset L, Dorizy-Duong V, Gérard E, Beylot-Barry M, Pham-Ledard A. Infiltration granulomateuse alopéciante du cuir chevelu sous mogamulizumab : 2 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Valentin J, Gérard E, Dousset L, Prey S, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Tolérance du cémiplimab en vie réelle : étude rétrospective monocentrique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Guicheney M, Pham-Ledard A, Beylot-Barry M, Dousset L, Prey S, Dutriaux C, Gerard E, Dequidt L. Encorafénib-binimétinib : des résultats encourageants notamment en intracrânien. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Marescassier H, Dousset L, Hainaut E, Bedane C, Vaillant L, Celerier P, Beylot-Barry M, Masson Regnault M. Facteurs prédictifs de non réponse au vismodégib dans les carcinomes basocellulaires localement avancés. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
22
|
Dousset L, Michon P, Hosseini M, Mahfouf W, Muzotte E, Taïeb A, Rezvani H. Profilage métabolique durant la photo-carcinogenèse : identification des vulnérabilités métaboliques au stade précoce et au stade avancé comme cible thérapeutique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.08.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Barailler H, Salomon G, Dutriaux C, Prey S, Gérard E, Dousset L, Mertens C, Beylot-Barry M, Meyer N, Pham-Ledard A. Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma. J Geriatr Oncol 2020; 11:1340-1343. [DOI: 10.1016/j.jgo.2020.03.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Revised: 12/16/2019] [Accepted: 03/04/2020] [Indexed: 11/27/2022]
|
24
|
Barailler H, Dousset L, Mertens C, Maurel A, Gérard E, Prey S, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Impact sur la qualité de vie et l’autonomie des patients de plus de 75 ans traités par anti-PD-1 pour un mélanome métastatique : étude prospective monocentrique. Ann Dermatol Venereol 2020; 147:713-720. [DOI: 10.1016/j.annder.2020.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 06/26/2020] [Accepted: 07/17/2020] [Indexed: 10/23/2022]
|
25
|
Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, Bourseau Quetier C, Cambon L, Cazanave C, Colin A, Kostrzewa E, Lesort C, Levy Roy A, Lombart F, Marco-Bonnet J, Monfort JB, Samimi M, Tardieu M, Wolkenstein P, Sbidian E, Beylot-Barry M. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. Br J Dermatol 2020; 183:866-874. [PMID: 32628270 PMCID: PMC7361395 DOI: 10.1111/bjd.19377] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/26/2020] [Indexed: 01/21/2023]
Abstract
Background Acral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID‐19. In more than 80% of patients tested, nasopharyngeal swabs were negative on reverse transcription polymerase chain reaction (RT‐PCR) for SARS‐CoV‐2 when performed, and serology was generally not performed. Methods A national survey was launched on 30 March 2020 by the French Society of Dermatology asking physicians to report cases of skin manifestations in patients with suspected or confirmed COVID‐19 by using a standardized questionnaire. We report the results for acral manifestations. Results We collected 311 cases of acral manifestations [58.5% women, median age 25.7 years (range 18–39)]. The most frequent clinical presentation (65%) was typical chilblains. In total, 93 cases (30%) showed clinical suspicion of COVID‐19, 67 (22%) had only less specific infectious symptoms and 151 (49%) had no clinical signs preceding or during the course of acral lesions. Histology of skin biopsies was consistent with chilblains. Overall, 12 patients showed significant immunological abnormalities. Of the 150 (48%) patients who were tested, 10 patients were positive. Seven of 121 (6%) RT‐PCR‐tested patients were positive for SARS‐CoV‐2, and five of 75 (7%) serology‐tested patients had IgG anti‐SARS‐CoV‐2. Tested/untested patients or those with/without confirmed COVID‐19 did not differ in age, sex, history or acral lesion clinical characteristics. Conclusions The results of this survey do not rule out that SARS‐CoV‐2 could be directly responsible for some cases of chilblains, but we found no evidence of SARS‐CoV‐2 infection in the large majority of patients with acral lesions during the COVID‐19 lockdown period in France. What is already known about this topic? About 1000 cases of acral lesions, mainly chilblains, were reported during the COVID‐19 outbreak. Chilblains were reported to occur in young people within 2 weeks of infectious signs, which were mild when present. Most cases did not have COVID‐19 confirmed by reverse transcription polymerase chain reaction (RT‐PCR), and few serology results were available.
What does this study add? Among 311 patients with acral lesions, mainly chilblains, during the COVID‐19 lockdown period in France, the majority of patients tested had no evidence of SARS‐CoV‐2 infection. Overall, 70 of 75 patients were seronegative for SARS‐Cov‐2 serology and 114 of 121 patients were negative for SARS‐CoV‐2 RT‐PCR.
Collapse
Affiliation(s)
- L Le Cleach
- Dermatology Department, Hôpital Henri Mondor, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - L Dousset
- Dermatology Department, University Hospital Bordeaux, Bordeaux, France
| | - H Assier
- Dermatology Department, Hôpital Henri Mondor, Créteil, France
| | - S Fourati
- Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
| | - S Barbarot
- Department of Dermatology, Nantes Université, CHU Nantes, UMR 1280 PhAN, INRAE, F-44000, Nantes, France
| | - C Boulard
- Le Havre Hospital, Department of Dermatology, 76600, Le Havre, France
| | | | - L Cambon
- Private Practice, rue de la Balance, Toulouse, France
| | - C Cazanave
- Infectious Diseases, University Hospital Bordeaux, Bordeaux, France
| | - A Colin
- Dermatology Department, Hôpital Henri Mondor, Créteil, France
| | - E Kostrzewa
- Dermatology Department, Hôpital Robert Boulin, Libourne, France
| | - C Lesort
- Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - A Levy Roy
- Private Practice, Avenue du Général de Gaulle, 13410, Lambesc, France
| | - F Lombart
- Dermatology, Amiens University Hospital Centre, Amiens, France
| | - J Marco-Bonnet
- Private practice, Avenue Pierre Brossolette 92120, Montrouge, France
| | - J-B Monfort
- Sorbonne Université, Paris, France.,Dermatology and Allergology Department, AP-HP, Hôpital Tenon, F-75020, Paris, France
| | - M Samimi
- Dermatology Department, University Hospital of Tours, ISP1282 INRA-University of Tours, Tours, France
| | - M Tardieu
- Dermatology Department, Centre Hospitalier Universitaire Grenoble Alpes, 38700, La Tronche, France
| | - P Wolkenstein
- Dermatology Department, Hôpital Henri Mondor, Créteil, France
| | - E Sbidian
- Dermatology Department, Hôpital Henri Mondor, Créteil, France.,EA 7379 EpiDermE, UPEC, Créteil, France
| | - M Beylot-Barry
- Dermatology Department, University Hospital Bordeaux, Bordeaux, France.,French Society of Dermatology, Paris, France
| | | |
Collapse
|
26
|
Berard E, Barnetche T, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T, Kostine M. SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Description and initial management of rheumatic immune-related adverse-events (irAEs) from cancer immunotherapies have been reported by several groups but to date, few studies have evaluated the long-term outcomes and management of rheumatic irAEs (1).Objectives:To describe the long-term management and assess the one-year outcomes of patients who experienced rheumatic immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI).Methods:This was a single-centre prospective observational study including patients referred for musculoskeletal symptoms while treated with ICI. After baseline rheumatological evaluation defining the clinical entity presented, follow-up visits were organised according to the type and severity of irAE. At one year, persistence of irAE, ongoing treatment, as well as cancer outcomes were assessed.Results:63 patients were included between September 2015 and June 2018. 24 patients (38%) presented with non-inflammatory musculoskeletal conditions managed with short-term symptomatic treatment and did not require specific follow-up. 39 patients (62%) experienced inflammatory manifestations, mimicking either rheumatoid arthritis (RA, n=19), polymyalgia rheumatica (PMR, n=16), psoriatic arthritis (PsA, n=3) and one flare of a preexisting axial spondyloarthritis. Overall, 32 patients (82%) received systemic glucocorticoids, with a median rheumatic dosage of 15mg/day (range: 5-60mg/day). None of the patients had to permanently discontinue ICI therapy for rheumatic irAE. 20 patients (67%) were still receiving glucocorticoids at one year, with a median dosage of 5mg/day (range: 2-20mg/day). Glucocorticoids were more frequently discontinued for patients with RA-like condition (44%) than PMR-like condition (23%), but no other predictive factor of glucocorticoids withdrawal could be identified. At one year, overall survival and progression-free survival were comparable between patients who were still receiving glucocorticoids for rheumatic irAE and patients who have discontinued. Eight patients required csDMARDs.Conclusion:At one year, a majority of patients required long-term low-dose glucocorticoids for chronic rheumatic irAE, which seems not altering oncological control.References:[1]Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2019 Sep 20.Disclosure of Interests:None declared
Collapse
|
27
|
Malmontet T, Dousset L, Gerard E, Ouhabrache N, Pham-Ledard A, Beylot-Barry M. [Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma]. Ann Dermatol Venereol 2019; 147:228-232. [PMID: 31791649 DOI: 10.1016/j.annder.2019.08.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 07/07/2019] [Accepted: 08/22/2019] [Indexed: 01/27/2023]
Abstract
INTRODUCTION Vismodégib is the first-line treatment for non-operable or metastatic locally advanced basal cell carcinomas (LABCC), although complete response is rare and adverse effects are common. Immune checkpoint inhibitors are currently being evaluated in this indication. Herein we report a case of LABCC that responded dramatically to sequenced "immunotherapy then radiotherapy". OBSERVATION A 47-year-old male presented peri- and intra-orbital infiltrative LABCC that had been present for more than 10 years. After an initial response to vismodégib, further disease progression resulted in the introduction of successive lines of treatment (radiotherapy, platinum salts and itraconazole) without any significant response. Compassionate treatment with pembrolizumab was initiated. After eight courses, major clinical progression occurred with intraoral extension responsible for respiratory discomfort. Following withdrawal of pembrolizumab, high-energy radiotherapy was started with a spectacular response, both clinically and in terms of imaging. DISCUSSION The efficacy of "radiotherapy-immunotherapy" sequencing in melanoma has been reported, due in particular to the abscopal effect and radiosensitisation. In our case, where the sequence was inverted, immunotherapy may have enhanced the effects of radiotherapy through "immunosensitisation", whereas radiotherapy alone had previously been ineffective. This observation underlines the potential value of these treatments, either combined or in sequence, and their synergistic effects and optimal association require further evaluation.
Collapse
Affiliation(s)
- T Malmontet
- Service de dermatologie, CHU de Bordeaux, hôpital Saint-André, rue Jean-Burguet, 33000 Bordeaux, France
| | - L Dousset
- Service de dermatologie, CHU de Bordeaux, hôpital Saint-André, rue Jean-Burguet, 33000 Bordeaux, France
| | - E Gerard
- Service de dermatologie, CHU de Bordeaux, hôpital Saint-André, rue Jean-Burguet, 33000 Bordeaux, France
| | - N Ouhabrache
- Service de radiothérapie, CHU de Bordeaux, hôpital Haut Lévêque, 33600 Pessac, France
| | - A Pham-Ledard
- Service de dermatologie, CHU de Bordeaux, hôpital Saint-André, rue Jean-Burguet, 33000 Bordeaux, France
| | - M Beylot-Barry
- Service de dermatologie, CHU de Bordeaux, hôpital Saint-André, rue Jean-Burguet, 33000 Bordeaux, France.
| |
Collapse
|
28
|
Manson G, Maria ATJ, Poizeau F, Danlos FX, Kostine M, Brosseau S, Aspeslagh S, Du Rusquec P, Roger M, Pallix-Guyot M, Ruivard M, Dousset L, Grignou L, Psimaras D, Pluvy J, Quéré G, Grados F, Duval F, Bourdain F, Maigne G, Perrin J, Godbert B, Taifas BI, Forestier A, Voisin AL, Martin-Romano P, Baldini C, Marabelle A, Massard C, Honnorat J, Lambotte O, Michot JM. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer 2019; 7:337. [PMID: 31796119 PMCID: PMC6892018 DOI: 10.1186/s40425-019-0821-8] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 11/13/2019] [Indexed: 02/07/2023] Open
Abstract
Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to describe the outcome for patients with a pre-existing or newly diagnosed PNS following the initiation of anti-PD-1 or anti-PD-L1 immunotherapy. Methods We included all adult patients (aged ≥18) treated with anti-PD-1 or anti-PD-L1 immunotherapy for a solid tumor, diagnosed with a PNS, and registered in French pharmacovigilance databases. Patients were allocated to cohorts 1 and 2 if the PNS had been diagnosed before vs. after the initiation of immunotherapy, respectively. Findings Of the 1304 adult patients screened between June 27th, 2014, and January 2nd, 2019, 32 (2.45%) had a PNS and were allocated to either cohort 1 (n = 16) or cohort 2 (n = 16). The median (range) age was 64 (45–88). The tumor types were non-small-cell lung cancer (n = 15, 47%), melanoma (n = 6, 19%), renal carcinoma (n = 3, 9%), and other malignancies (n = 8, 25%). Eleven (34%) patients presented with a neurologic PNS, nine (28%) had a rheumatologic PNS, eight (25%) had a connective tissue PNS, and four (13%) had other types of PNS. The highest severity grade for the PNS was 1–2 in 10 patients (31%) and ≥ 3 in 22 patients (69%). Four patients (13%) died as a result of the progression of a neurologic PNS (encephalitis in three cases, and Lambert-Eaton syndrome in one case). Following the initiation of immunotherapy, the PNS symptoms worsened in eight (50%) of the 16 patients in cohort 1. Interpretation Our results show that PNSs tend to be worsened or revealed by anti-PD-1 or anti-PD-L1 immunotherapy. Cases of paraneoplastic encephalitis are of notable concern, in view of their severity. When initiating immunotherapy, physicians should carefully monitor patients with a pre-existing PNS.
Collapse
Affiliation(s)
- Guillaume Manson
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.,Department of Hematology, University Hospital of Rennes, Rennes, France
| | - Alexandre Thibault Jacques Maria
- Department of Internal Medicine and Multiorgan Diseases, Referral Center for Auto-immune Diseases, Saint-Eloi Hospital Montpellier University, Montpellier, France
| | - Florence Poizeau
- Department of Dermatology, Rennes University Hospital, Rennes, France
| | - François-Xavier Danlos
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Marie Kostine
- Rheumatology Department, Bordeaux University Hospital, Bordeaux, France
| | - Solenn Brosseau
- AP-HP, Hôpital Bichat-Claude Bernard, Centre Investigation Clinique 1425, Thoracic Oncology Department, University Paris-Diderot, Paris, France
| | - Sandrine Aspeslagh
- Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
| | - Pauline Du Rusquec
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France
| | - Maxime Roger
- Department of Pulmonology and Thoracic Oncology, Rouen University Hospital, Rouen, France
| | | | - Marc Ruivard
- Internal Medicine Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Léa Dousset
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | | | - Dimitri Psimaras
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin et Université Pierre et Marie Curie-Paris 6, Centre de Compétence des Syndromes Neurologiques Paranéoplasiques et Encéphalites Auto-immunes, Paris, France
| | - Johan Pluvy
- AP-HP, Hôpital Bichat-Claude Bernard, Centre Investigation Clinique 1425, Thoracic Oncology Department, University Paris-Diderot, Paris, France
| | - Gilles Quéré
- Oncology Departement, Brest Hôpital Morvan Centre Hospitalier Régional Universitaire, Brest, France
| | - Franck Grados
- Amiens University Hospital, Rheumatology Department, University of Picardie - Jules Verne, Amiens, France
| | - Fanny Duval
- Neurology Department, Bordeaux University Hospital, Bordeaux, France
| | - Frederic Bourdain
- Departement de Neurologie, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Gwenola Maigne
- Department of Internal Medicine, Caen University Hospital, Caen, France
| | - Julie Perrin
- Pneumology Department, Metz Robert Schuman Hospital, Metz, France
| | - Benoit Godbert
- Pneumology Department, Metz Robert Schuman Hospital, Metz, France
| | | | | | - Anne-Laure Voisin
- Gustave Roussy, Université Paris-Saclay, Unité fonctionnelle de Pharmacovigilance, F-94805, Villejuif, France
| | - Patricia Martin-Romano
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Capucine Baldini
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Aurélien Marabelle
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Christophe Massard
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Jérôme Honnorat
- Hospices Civils de Lyon, French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, SynatAc Team, Institut NeuroMyoGène. INSERM U1217/CNRS UMR 5310, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Olivier Lambotte
- AP-HP, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin-Bicêtre, France.,Université Paris Sud, Centre de Recherche en Immunologie des Infections Virales et des Maladies Auto-Immunes, INSERM U1184, Le Kremlin-Bicêtre, France.,Division d'Immunovirologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Fontenay-aux- Roses, France
| | - Jean-Marie Michot
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
| |
Collapse
|
29
|
Bourlond F, Battistella M, Dousset L, Amici JM, Tuzin N, Vergier B, Beylot-Barry M, Cribier B. Étude clinique de 62 trichoblastomes et comparaison au carcinome basocellulaire nodulaire. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Valentin J, Ferté T, Dorizy-Vuong V, Dousset L, Dutriaux C, Prey S, Pham-Ledard A, Beylot-Barry M, Gérard E. Survie des patients traités pour un mélanome métastatique après arrêt de l’immunothérapie pour réponse objective ou toxicité : étude rétrospective de cohorte. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Canu D, Gerard E, Dousset L, Soulages A, Dutriaux C. Effets secondaires neurologiques sévères chez 5 patients traités par anti-PD-1 pour un mélanome métastatique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Barailler H, Dousset L, Mertens C, Gerard E, Prey S, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Étude prospective sur une série de patients ≥ 75 ans traités par anti-PD-1 pour un mélanome métastatique: impact sur l’autonomie et la qualité de vie. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
33
|
Drissi-Bakhkhat A, Guicheney M, Dutriaux C, Cirotteau P, Milpied B, Chan H, Dousset L, Duffau P, Seneschal J. Ophtalmoplégie isolée au cours d’un traitement par double immunothérapie pour un mélanome métastatique. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Pacaud A, Amintas S, Dousset L, Boussemart L, Dutriaux C, Cappellen D, Gérard E. Une réponse surprenante aux anti-MEK. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Dousset L, Boussemart L, Robert C, Mansard S, Lebbe C, Merlio JP, Routier E, Dupuy A, Rouanet J, Battistella M, Capellen D, Galibert MD, Allayous C, Lespagnol A, Villechenoux G, Gerard E, Kerneuzet I, Roy S, Vergier B, Beylot-Barry M. Tumour mutational burden and response to PD-1 inhibitors: An analysis of 89 cases of metastatic melanoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Cirotteau P, Lucas P, Dousset L, Cales V, Gilliot O, Jouary T. Radiation-induced Bullous Lichen Planus: An Isomorphic Manifestation of Radiotherapy. Acta Derm Venereol 2019; 99:1033-1034. [PMID: 31289839 DOI: 10.2340/00015555-3258] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Paul Cirotteau
- Department of Dermatology, Centre hospitalier de Pau, 64000 PAU, France
| | | | | | | | | | | |
Collapse
|
37
|
Martin M, Atallah V, Prey S, Gérard E, Amestoy F, Benziane N, Leduc N, Huchet A, Beylot-Barry M, Dupin C, Nora O, Dutriaux C, Trouette R, Dousset L, Vendrely V. Radiothérapie concomitante chez des patients pris en charge par immunothérapie pour mélanome avec mutation de B-RAF après thérapie ciblée : étude monocentrique comparative sur 114 patients. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Hosseini M, Dousset L, Mahfouf W, Muzotte E, Taieb A, Rezvani H. 462 DHODH inhibition for chemoprevention and combination therapy of UVB-induced epithelial oncogenesis. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
39
|
Mahfouf W, Muzotte E, Dousset L, Moisan F, Taieb A, Rezvani H. 463 Hypoxia-inducible factor-1α play a critical role in UVB-induced tumorigenesis by affecting DNA repair capacity and oxidative stress. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Benziane N, Atallah V, Amestoy F, Gerard E, Leduc N, Huchet A, Barry MB, Dupin C, Prey S, Dousset L, Ouabrache N, Martin M, Gillon P, Dutriaux C, Trouette R, Vendrely V. EP-1596 Radiotherapy and Ipilimumab as first-line immunotherapy: A comparative study on 63 patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32016-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Abstract
Antibody-based therapeutics targeting programmed cell death 1 (PD-1) have shown strong efficacy in the treatment of metastatic cancers as melanoma. However, restoring the immune function with these therapies to target cancer cells leads to immune side effects including immune cutaneous events. Vitiligo-like lesions in patients receiving anti-PD-1 is one of the most common skin adverse event reported and the incidence seems to be higher than in patients receiving other immune-checkpoints therapies. Initially described in patients with metastatic melanoma, vitiligo-like lesions have now been reported in other metastatic cancers treated with anti-PD-1. Several reports suggest that this side effect could be different from spontaneously occurring vitiligo and could be associated with increased response to the therapy and patients' survival. The aim of this review is to provide an overview of the clinical presentation of vitiligo-like lesions occurring in patients receiving anti-PD-1, and the hypothesis to explain the mechanism involved in the development of these lesions.
Collapse
Affiliation(s)
- Léa Dousset
- Department of Dermatology and Pediatric Dermatology, National Center for Rare Skin Disorders, Saint-André and Pellegrin Hospitals, Bordeaux, France
| | | | - Julien Seneschal
- Department of Dermatology and Pediatric Dermatology, National Center for Rare Skin Disorders, Saint-André and Pellegrin Hospitals, Bordeaux, France - .,INSERM U1035, University of Bordeaux, Bordeaux, France
| |
Collapse
|
42
|
Kerneuzet I, Lespagnol A, Rioux-Leclerc N, Dinulescu M, Lesimple T, Dousset L, Gérard E, Beylot-Barry M, Dupuy A, Prey S, Caumont C, Capellen D, Merlio JP, Galibert MD, Boussemart L. Séquençage nouvelle génération (NGS) de mélanomes à partir d’un panel de 315 gènes et 28 introns : intérêt clinique de l’identification de mutations pathogènes hors BRAF/NRAS/KIT dans la vraie vie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Dequidt L, Dousset L, Pham-Ledard A, Doutre MS, Beylot-Barry M. Long-lasting cutaneous tuberculosis owing to Mycobacterium bovis masquerading as sarcoidosis. JAAD Case Rep 2018; 5:1-4. [PMID: 30533472 PMCID: PMC6262779 DOI: 10.1016/j.jdcr.2018.07.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Affiliation(s)
- Laure Dequidt
- Dermatology Department, University Hospital of Bordeaux, Bordeaux, France
| | - Léa Dousset
- Dermatology Department, University Hospital of Bordeaux, Bordeaux, France
| | - Anne Pham-Ledard
- Dermatology Department, University Hospital of Bordeaux, Bordeaux, France
| | | | - Marie Beylot-Barry
- Dermatology Department, University Hospital of Bordeaux, Bordeaux, France
| |
Collapse
|
44
|
Atallah V, Amestoy F, Gerard E, Leduc N, Huchet A, Beylot-Barry M, Dupin C, Prey S, Dousset L, Trouette R, Ouabrache N, Maillot O, Martin M, Gillon P, Dutriaux C, Vendrely V. Concurrent Radiation Therapy for Patients with Metastatic Melanoma and Receiving Anti-Programmed-Death 1 Therapy: A Retrospective Monocentric Study on 141 Patients. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Kostine M, Dousset L, Schaeverbeke T. Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and Bass. Ann Rheum Dis 2018; 78:e71. [PMID: 29925509 DOI: 10.1136/annrheumdis-2018-213682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 06/08/2018] [Indexed: 11/04/2022]
Affiliation(s)
- Marie Kostine
- Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Léa Dousset
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Thierry Schaeverbeke
- Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | | |
Collapse
|
46
|
Lamoureux A, Ouhabrache N, Coulibaly S, Dousset L, Gerard E, Dutriaux C, Pham-Ledard A, Cogrel O, Trouette R, Beylot-Barry M, Vendrely V. PO-0835: Contact Radiotherapy For Lentigo Maligna And Lentigo Maligna Melanoma: A Cohort Of 61 Cases. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31145-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Ducharme O, Prey S, Gérard E, Pham-Ledard A, Dousset L, Haissaiguerre M, Dutriaux C. Dysthyroïdies sous immunothérapie dans le mélanome : l’expérience du CHU de Bordeaux. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Larsabal M, Marti A, Dousset L, Jacquemin C, Boniface K, Taieb A, Dutriaux C, Prey S, Seneschal J. Vitiligo-like sous immunothérapie anti-PD1 cliniquement et biologiquement distinct du vitiligo spontané ? Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
49
|
Amico S, Dousset L, Mermin D, Boniface K, Jacquemin C, Dutriaux C, Beylot-Barry M, Seneschal J. Réponse complète après deux perfusions d’un mélanome localement avancé sous anti-PD-1 : rôle de lymphocytes T dits résidents mémoires. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Dousset L, Amici JM, Cribier B, Battistella M, Vergier B, Bailly JY, Cogrel O, Alfaro C, Ezzedine K, Beylot-Barry M. Étude prospective multicentrique de 2710 carcinomes basocellulaires : concordance entre agressivité clinique supposée et agressivité histologique. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|